Market Overview

H Michael Cohen Joins Masimo's Board of Directors

Share:

Masimo (NASDAQ: MASI), a global medical technology developer and manufacturer of
innovative noninvasive patient monitoring technologies, announced today
that H Michael Cohen, former Vice Chairman of Healthcare Investment
Banking at Deutsche Bank Securities, has been elected to Masimo's Board
of Directors.

Mr. Cohen has almost 30 years of experience in the healthcare industry.
Over the past 19 years, he has held various roles at Deutsche Bank,
including Global Head, Healthcare Investment Banking and most recently
Vice Chairman, Healthcare Investment Banking. Prior to joining Deutsche
Bank, Mr. Cohen worked at SG Cowen, Union Bank of Switzerland, and Booz
Allen Hamilton. Mr. Cohen began his career in healthcare at Hambrecht &
Quist, where he was a member of the equity research team covering
biotechnology, medical device, and diagnostic companies. He received his
B.A. in Economics from the University of Vermont and his M.B.A. from
Columbia University.

Joe Kiani, Founder, Chairman and CEO of Masimo, said, "We're thrilled to
welcome Michael to our Board of Directors. With his vast experience in
healthcare investment banking and deep understanding of the medical
technology industry and the complexities of global healthcare, he'll be
an excellent addition. We look forward to benefiting from his expertise
and insight as Masimo continues to grow."

"I'm honored to join Masimo's Board," said Mr. Cohen. "It's been a
privilege to observe Masimo grow from its humble beginning in 1989 into
the global leader in noninvasive monitoring it has become today, and I'm
excited to help shape the next stage of its journey while driving
long-term value for Masimo and its shareholders."

@MasimoInnovates |
#Masimo

About Masimo

Masimo (NASDAQ:MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.

ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.

The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.

References

  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
    Infants through Changes in Clinical Practice and SpO2
    Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
    detection of duct dependent congenital heart disease: a Swedish
    prospective screening study in 39,821 newborns. BMJ. 2009;Jan
    8;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
    Events and Intensive Care Unit Transfers: A Before-And-After
    Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
    Patient Safety Foundation Newsletter
    . Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care
    Units: Strategy, Design, and Implementation. The Joint Commission
    Journal on Quality and Patient Safety
    . 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.
  7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique advantages; as
well as other factors discussed in the "Risk Factors" section of our
most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.

View Comments and Join the Discussion!